This study aimed to compare pCR rates, tolerability and early cardiac safety of the two commonly used neoadjuvant regimens in locally advanced HER2-positive breast cancer in a real-life population: the anthracycline-containing ACTHP versus the anthracycline-free DCbHP regimen. This evidence concerns the gene ERBB2 and breast carcinoma.